IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial results for the third quarter ended September 30, 2025.
"This quarter we continued to make significant progress across the pipeline and broader business, including the partnership with Servier that extends our runway into 2030 and enables potential commercialization of darovasertib outside of the United States. We have also provided multiple major medical conference clinical data updates at WCLC, ESMO and SMR, and completed our third IND filing in 2025 to further extend our industry leadership in precision medicine oncology," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.
Selected Pipeline Developments and Upcoming Milestones
Darovasertib
IDE397 (MAT2A)
IDE849 (DLL3 TOP1i ADC)
Other programs
License agreement with Servier
Financial Results for the Quarter Ended September 30, 2025
As of September 30, 2025, IDEAYA had cash, cash equivalents and marketable securities of approximately $1.14 billion, compared to $991.9 million as of June 30, 2025. The increase was primarily driven by the $210.0 million upfront payment received from Servier related to the exclusive license agreement for darovasertib, offset by the net cash used in operations.
Collaboration revenue for the three months ended September 30, 2025, totaled $207.8 million compared to zero for the three months ended June 30, 2025. Collaboration revenue was recognized for the performance obligations satisfied through September 30, 2025 related to the development and commercialization license recognized upon execution and the research and development services that will be recognized over time under the Servier exclusive license agreement for darovasertib. As of September 30, 2025, the remaining balance for the research and development services performance obligations is $143.1 million related to the clinical development cost reimbursements anticipated under the license agreement that will be recognized as IDEAYA collaboration revenue over time as the research and development services are completed.
Research and development (R&D) expenses for the three months ended September 30, 2025 totaled $83.0 million compared to $74.2 million for the three months ended June 30, 2025. The increase was primarily driven by higher clinical trial and CMC manufacturing expenses to support our programs.
General and administrative (G&A) expenses for the three months ended September 30, 2025 totaled $16.4 million compared to $14.6 million for the three months ended June 30, 2025. The increase was primarily due to higher legal expenses to support company growth and commercial expenses to support the darovasertib commercial preparation activities.
The net income for the three months ended September 30, 2025, was $119.2 million compared to the net loss of $77.5 million for the three months ended June 30, 2025. Total stock compensation expense for the three months ended September 30, 2025, was $12.2 million compared to $11.9 million for the three months ended June 30, 2025.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer. IDEAYA's corporate presentation is available on its website: https://ir.ideayabio.com/.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to (i) the timing and content of clinical trial programs and updates, including enrollment achievements, regulatory updates, clinical trial data readouts, including those at medical conferences; (ii) the potential for an accelerated approval filing for darovasertib; (iii) the potential therapeutic benefits of IDEAYA therapeutics; (iv) the translation of preliminary clinical trial results into future clinical trial results and/or regulatory approval; (v) timing of development and regulatory milestones; (vi) the timing of new IND application filings; (vii) the potential for milestone payments, royalties and clinical development cost sharing under the Servier License Agreement; and (viii) the extent to which IDEAYA's existing cash, cash equivalents, and marketable securities will fund its planned operations. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing and commercializing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
IDEAYA Biosciences, Inc.
Condensed Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share amounts)
Three Months Ended
Nine Months Ended
September 30,
2025
June 30, 2025
September 30,
2025
September 30,
2024
(Unaudited)
(Unaudited)
Collaboration revenue
$
207,834
$
—
$
207,834
$
—
Total revenue
207,834
—
207,834
—
Operating expenses:
Research and development
$
82,993
$
74,226
$
228,105
$
154,490
General and administrative
16,389
14,580
44,472
28,347
Total operating expenses
99,382
88,806
272,577
182,837
Income (loss) from operations
108,452
(88,806)
(64,743)
(182,837)
Interest income and other income,
net
10,792
11,315
34,318
38,672
Net income (loss)
119,244
(77,491)
(30,425)
(144,165)
Unrealized gains on marketable
securities
531
(64)
1,240
3,274
Comprehensive income (loss)
$
119,775
$
(77,555)
$
(29,185)
$
(140,891)
Net income (loss) per share
attributable to common
stockholders, basic
$
1.35
$
(0.88)
$
(0.34)
$
(1.81)
Weighted-average number of shares
outstanding, basic
88,526,781
88,472,197
88,452,395
79,776,728
Net income (loss) per share
attributable to common
stockholders, diluted
$
1.33
$
(0.88)
$
(0.34)
$
(1.81)
Weighted-average number of shares
outstanding, diluted
89,690,878
88,472,197
88,452,395
79,776,728
IDEAYA Biosciences, Inc.
Condensed Balance Sheet Data
(in thousands)
September 30,
December 31,
2025
2024
(Unaudited)
Cash and cash equivalents and short-term and long-term
marketable securities
$
1,136,854
$
1,082,151
Total assets
1,185,136
1,124,091
Total liabilities
93,102
64,944
Total liabilities and stockholders' equity
$
1,185,136
$
1,124,091
SOURCE IDEAYA Biosciences, Inc.